A Phase Ib Open-Label study of the Safety and Clinical Activity of Crizotinib (PF-02341066) in Tumors with Genetic Events Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
The purpose of this study is to see whether crizotinib (the study drug) is safe and effective at slowing the growth of cancer.
Advanced cancer (other than non-small cell lung cancer) with a specific type of genetic makeup called an "ALK genetic event."
*Diagnosis of advanced malignancy (other than non-small cell lung cancer) with no standard therapy available
*Positive for ALK genetic event
*Male of female subjects at least 18 years of age
*Prior treatment must be completed at least 4 weeks before starting study drug
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until your cancer gets worse
Amy Henderson, RN